Virbac : annual sales growth of 4.5%, at constant exchange rates
(Thomson Reuters ONE) -
Virbac: annual sales growth of 4.5%, at constant exchange rates
Public release - January 17(th), 2017
Virbac consolidated revenue in the fourth quarter reached 225.7 M?, a
significant +9.2% growth compared to the same period of last year and a +8.6%
increase at constant scope. Growth was driven primarily by sales in the United
States of historical ranges, including internal parasiticides (lverhart Plus and
Iverhart Max reintroduction), as well as dentals and dermatology ranges. Good
performances in Italy, Spain, Australia, and China also contributed to growth.
It should also be noted that the United States benefited from a storage effect
in distributors in 2016, with a return to the market for certain products at the
end of the year, in particular Iverhart Max, as well as a gradual recovery of
sales to clinics of reintroduced products.
Total 2016 annual sales reached 871.9 M? compared to 852.6 M? last year, a
+2.3% overall growth, of which +4.5% excluding unfavorable exchange rates
impact. All regions show positive developments with the exception of Chile. In
the United States, historical ranges, including dentals and dermatology,
continued to grow. The Iverhart Plus and Iverhart Max range of internal
parasiticides benefited from a favorable base effect over the year and showed a
good increase compared to the same period of 2015, while being below the
prospects due to a return on the market slower than expected. The Sentinel line
is down because of increased competition in the internal parasiticides segment,
which is also in a slight decline. Europe was up by 4.6% at comparable rates,
notably as a result of sustained activity in France thanks to recent launches of
parasiticides products and a favorable base effect due to low sales of
antibiotics in 2015, as well as the performance of the United Kingdom, Italy,
Greece and Spain. In the other regions, emerging countries contributed strongly
to organic growth thanks to the dynamism of India on ruminant ranges, including
nutritional supplements, parasiticides and antibiotics, from China with good
performance on companion animals products (Zoletil, Epiotic, Rilexine) and on
the industrial range, in Brazil and Mexico, notably on antibiotics for ruminants
(Multibio, Shotapen, Fortius).
In terms of species, revenue in the companion animals segment increased by
+6.2% and +7.7% at constant parities. This good performance is due to the
gradual recovery of sales of historical products in the United States and the
ramp-up of new products launched recently in Europe, notably the Effitix and
Milpro parasiticides and the new nutrition range. The dentals, dermatology,
hygiene and specialities lines also contribute to this level of sustained
growth.
The food producing animals segment shows a negative evolution: -2.8%, of which
+0.3% at constant scope. The segment is strongly impacted by the situation in
Chile, which is down 18%. Outside of aquaculture, the two bovine and industrial
sectors (pigs and poultry) showed contrasting performances at constant rates and
perimeter respectively of + 6.2% and -0.7%. Growth was driven mostly by emerging
countries, mainly India, Brazil and China, as well as by New Zealand, while
activity in Europe was down in the industrial sector (pigs and poultry).
Perspectives
In the United States, the US subsidiary was finally notified by the FDA on 16
December of the lifting of the warning letter received in December 2015,
enabling the St. Louis site to recover its compliance status with Good
Manufacturing Practice (cGMP) and thereby the ability to file new registration
and variation files with the FDA, and to ensure the continued transfer of
production from Sentinel Spectrum to St. Louis as initially planned.
The Group current operating profit - adjusted is expected to exceed 10% at
constant exchange rates, while deleveraging has continued in the second half of
the year, which should lead to an annual decline in net debt of around ? 50
million. The Group's net debt to EBITDA ratio is expected to be around 4.5 at
constant exchange rates. It should, however, be above 4.5 at real rates. In view
of these factors, Virbac obtained from its pool of banks an easing of the
covenant clause at the end of 2016. The net debt to EBITDA ratio must now be
below 5.5 at actual rates versus 4.5 before. The discussion continues with
private investors (Schuldschein), representing approximately 15% of Virbac SA's
financing. Virbac also obtained from its pool of banks an easing of the covenant
clause for 2017 in the same proportions as in 2016.
Key figures
2016 NET REVENUE
Provisonal
871.9 M?
(_________)
TOTAL GROWTH
+2.3%
(_________)
GROWTH AT
CONSTANT EXCHANGE RATES
+4.5%
(_________)
GROWTH AT CONSTANT SCOPE
+4.4%
Of which :
COMPANION ANIMALS
+7.7%
FOOD PRODUCING ANIMALS
+0.3%
CONSOLIDATED DATA Evolution
Unaudited - in at constant Evolution at
million Euros 2016 2015 % change exchange rates constant scope
Net revenue - 1(st) 211.4 211.4 +0.0% +3.4% +3.3%
quarter
-------------------------------------------------------------------------------
Net revenue - 2(nd) 218.5 220.9 -1.1% +3.9% +3.7%
quarter
-------------------------------------------------------------------------------
Net revenue - 3(rd) 216.3 213.7 +1.2% +2.3% +2.2%
quarter
-------------------------------------------------------------------------------
Net revenue - 4(th) 225.7 206.6 +9.2% +8.6% +8.6%
quarter
-------------------------------------------------------------------------------
Net annual revenue 871.9 852.6 +2.3% +4.5% +4.4%
-------------------------------------------------------------------------------
Virbac: annual sales growth of 4.5%, at constant exchange rates :
http://hugin.info/136717/R/2071741/778552.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Virbac via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2017 - 17:45 Uhr
Sprache: Deutsch
News-ID 518156
Anzahl Zeichen: 7466
contact information:
Town:
Carros
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Virbac : annual sales growth of 4.5%, at constant exchange rates"
steht unter der journalistisch-redaktionellen Verantwortung von
Virbac (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
